Market closed

Phathom Pharmaceuticals/$PHAT

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Phathom Pharmaceuticals

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Ticker

$PHAT
Trading on

Industry

Pharmaceuticals

Employees

452

PHAT Metrics

BasicAdvanced
$574M
Market cap
-
P/E ratio
-$5.68
EPS
0.72
Beta
-
Dividend rate
$574M
0.72
$18.68
$6.07
1.6M
5.726
5.449
-266.214
-277.37
-4.33%
-57.67%
331.35%
19.093
-3.07
-3.07
-2.025
51.71%
8.21%

What the Analysts think about PHAT

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Phathom Pharmaceuticals stock.

PHAT Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

PHAT Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PHAT

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Phathom Pharmaceuticals stock?

Phathom Pharmaceuticals (PHAT) has a market cap of $574M as of December 13, 2024.

What is the P/E ratio for Phathom Pharmaceuticals stock?

The price to earnings (P/E) ratio for Phathom Pharmaceuticals (PHAT) stock is 0 as of December 13, 2024.

Does Phathom Pharmaceuticals stock pay dividends?

No, Phathom Pharmaceuticals (PHAT) stock does not pay dividends to its shareholders as of December 13, 2024.

When is the next Phathom Pharmaceuticals dividend payment date?

Phathom Pharmaceuticals (PHAT) stock does not pay dividends to its shareholders.

What is the beta indicator for Phathom Pharmaceuticals?

Phathom Pharmaceuticals (PHAT) has a beta rating of 0.72. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.